PEGYLATED INTERFERON-BETA VARIANTS

摘要

Provided are a PEGylated interferon-beta (IFN-β) mutant, and a composition which comprises the same as an active ingredient for preventing and treating hyperproliferative diseases, inflammatory diseases, auto-immune diseases, or virus infection diseases. Compared to the natural IFN-β and non-PEGylated IFN-β mutant, the PEGylated IFN-β mutant of the present invention has excellent pharmacodynamics characteristics such as anti-virus efficacy, immunomodulation function, and anti-cell growth activity, thereby being usefully applicable to various diseases. The PEGylated IFN-β mutant of the present invention shows excellent efficacy of pharmacologic activation upon administration and significantly increases half-life in blood compared to conventional interferon medicine, thereby having excellent patient convenience in the aspect of administration. The IFN-β mutant is PEGylated by CH3O-(CH2CH2O)n (n is an integer from 2 to 4,000) in an amine group, carboxyl group, or Cys residue covalently binding to carbonyl, amide, urethane, secondary amine, thioether, disulphide, or hydrazone.